163 related articles for article (PubMed ID: 7841038)
1. The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.
Millar BC; Bell JB; Barfoot R; Everard M
Br J Cancer; 1995 Feb; 71(2):259-64. PubMed ID: 7841038
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro.
Borinaga AM; Millar BC; Bell JB; Joffe JK; Millar JL; Gooding R; Riches P; McElwain TJ
Br J Haematol; 1990 Dec; 76(4):476-83. PubMed ID: 2265109
[TBL] [Abstract][Full Text] [Related]
3. A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro.
Millar BC; Bell JB; Lakhani A; Ayliffe MJ; Selby PJ; McElwain TJ
Br J Haematol; 1988 Jun; 69(2):197-203. PubMed ID: 3390392
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Liu P; Leong T; Quam L; Billadeau D; Kay NE; Greipp P; Kyle RA; Oken MM; Van Ness B
Blood; 1996 Oct; 88(7):2699-706. PubMed ID: 8839865
[TBL] [Abstract][Full Text] [Related]
5. In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
Millar BC; Bell JB; Maitland JA; Zuiable A; Gore ME; Selby PJ; McElwain TJ
Br J Haematol; 1989 Feb; 71(2):213-22. PubMed ID: 2923807
[TBL] [Abstract][Full Text] [Related]
6. N-ras and p53 gene mutations are very rare events in multiple myeloma.
Yasuga Y; Hirosawa S; Yamamoto K; Tomiyama J; Nagata K; Aokia N
Int J Hematol; 1995 Aug; 62(2):91-7. PubMed ID: 8590778
[TBL] [Abstract][Full Text] [Related]
7. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
Bell JB; Millar BC; Montes-Borinaga A; Joffe JK; Cunningham D; Mansi J; Treleaven J; Viner C; McElwain TJ
Hematol Oncol; 1990; 8(6):347-53. PubMed ID: 2286358
[TBL] [Abstract][Full Text] [Related]
8. Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.
Maitland JA; Millar BC; Bell JB; Montes A; Treleaven J; Gore ME; McElwain TJ
Br J Cancer; 1990 Mar; 61(3):429-33. PubMed ID: 2328211
[TBL] [Abstract][Full Text] [Related]
9. Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
[TBL] [Abstract][Full Text] [Related]
10. Ras oncogene mutation in multiple myeloma.
Neri A; Murphy JP; Cro L; Ferrero D; Tarella C; Baldini L; Dalla-Favera R
J Exp Med; 1989 Nov; 170(5):1715-25. PubMed ID: 2681517
[TBL] [Abstract][Full Text] [Related]
11. Comparison of interleukin-6 levels in the bone marrow of multiple myeloma patients with disease severity and clonogenicity in vitro.
Bell JB; Montes A; Gooding R; Riches P; Cunningham D; Millar BC
Leukemia; 1991 Nov; 5(11):958-61. PubMed ID: 1961036
[TBL] [Abstract][Full Text] [Related]
12. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.
Corradini P; Ladetto M; Voena C; Palumbo A; Inghirami G; Knowles DM; Boccadoro M; Pileri A
Blood; 1993 May; 81(10):2708-13. PubMed ID: 8490179
[TBL] [Abstract][Full Text] [Related]
13. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation.
Kalakonda N; Rothwell DG; Scarffe JH; Norton JD
Blood; 2001 Sep; 98(5):1555-60. PubMed ID: 11520807
[TBL] [Abstract][Full Text] [Related]
14. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R
Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732
[TBL] [Abstract][Full Text] [Related]
15. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
[TBL] [Abstract][Full Text] [Related]
16. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
17. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma.
Ortega MM; Faria RM; Shitara ES; Assis AM; Albuquerque DM; Oliveira JS; Noguti MA; Faria JR; Costa FF; Lima CS
Leuk Lymphoma; 2006 Feb; 47(2):285-9. PubMed ID: 16321859
[TBL] [Abstract][Full Text] [Related]
18. p53 and RAS gene mutations in multiple myeloma.
Portier M; Molès JP; Mazars GR; Jeanteur P; Bataille R; Klein B; Theillet C
Oncogene; 1992 Dec; 7(12):2539-43. PubMed ID: 1461658
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal acute myeloid leukemia cells in bone marrow by probing for mutated ras oncogenes using the polymerase chain reaction.
Ball ED; Mills LE; Neubauer A; Liu E
Prog Clin Biol Res; 1990; 333():499-506. PubMed ID: 2408063
[No Abstract] [Full Text] [Related]
20. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
